Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2023 · 10-Q
Revenue$83.00K$83.00K+12.2% vs Q1 2022 Net Income-$11.22M-$11.22MN/M vs Q1 2022 EPS Diluted-$0.25-$0.25N/M vs Q1 2022 Operating Income-$12,052,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Free Cash Flowderived-$8,667,000N/M Margins · derivedOperating margin-14520.5%+444.4 pt vs Q1 2022
Net margin-13521.7%+1333.7 pt vs Q1 2022
ended Mar 31, 2023 · filed May 4, 2023 · 34 d after period end